Completed PHASE3 INTERVENTIONAL 1-arm NCT00144612

Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP

Sponsor: Chugai Pharmaceutical

Conditions Systemic Juvenile Idiopathic Arthritis

Interventions MRA(Tocilizumab)

Updated 5 times since 2017 Last updated: Dec 21, 2009 Started: Jul 31, 2004 Primary completion: Jun 30, 2005 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Systemic Juvenile Idiopathic Arthritis and is currently completed. Chugai Pharmaceutical leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chugai Pharmaceutical

Data source: Chugai Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.